UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial
December 05, 2017 at 10:08 AM EST
Dec 5 (Reuters) - Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.